Medication treatments for ADHD B for diagnosis codes and have known side effects and need to follow-up codes be closely monitored by a F for medication list prescribing practitioner. 19. Use of a stimulant % of enrollees 18 years of age Numerator: Those children from the Attention Deficit/Hyperactivity Medicaid Claims & Encounter B medication for ADHD or younger diagnosed with denominator who received a Disorder (ADHD) is a common Data ADHD who receive a stimulant stimulant medication psychiatric condition with an Pharmacy Files medication during the estimated prevalence between 3% Eligibility Files measurement year Denominator: The total number of and 6% among school-aged children Professional Files children with continuous enrollment in the United States. Inpatient Files and diagnosed with treatment options for ADHD disorder (ADHD) include medication, environmental during the measurement year. and behavioral modification, and interventions addressing skill deficits See Appendix F for stimulant or psychological issues. Studies medication list have shown that stimulant medication is relatively safe and efficacious for short-term treatment of inattentiveness, impulsivity and hyperactivity. 20. Higher than recommended % of enrollees 18 years of age Numerator: Those in the denominator While the most effective and Medicaid Claims & Encounter B dose of ADHD or younger on ADHD with evidence of a dose higher than tolerable dose of medication varies Data medications medications with evidence of a the recommended maximum from individual to individual, studies Pharmacy Files dose higher than the suggest that doses higher than Eligibility Files recommended maximum during Denominator: The number of children recommended are not generally the measurement period 18 years of age or younger who were associated with improved clinical prescribed at least one stimulant response. High dosing also medication for 30 days or more increases the risk for poor during the measurement year adherence and adverse side effects. Research suggests that children and See Appendix D for ADHD dose youth are particularly vulnerable to guidelines adverse effects of psychotropic medications. In children, high doses of stimulants can cause insomnia and appetite suppression.
B for diagnosis codes and follow-up codes F for medication list Medication treatments for ADHD have known side effects and need to be closely monitored by a prescribing practitioner. 19. Use of a stimulant medication for ADHD % of enrollees 18 years of age or younger diagnosed with ADHD who receive a stimulant medication during the measurement year Numerator: Those children from the denominator who received a stimulant medication Denominator: The total number of children with continuous enrollment and diagnosed with disorder (ADHD) during the measurement year. See Appendix F for stimulant medication list Attention Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric condition with an estimated prevalence between 3% and 6% among school-aged children in the United States. treatment options for ADHD include medication, environmental and behavioral modification, and interventions addressing skill deficits or psychological issues. Studies have shown that stimulant medication is relatively safe and efficacious for short-term treatment of inattentiveness, impulsivity and hyperactivity. Medicaid Claims & Encounter Data Pharmacy Files Eligibility Files Professional Files Inpatient Files B 20. Higher than recommended dose of ADHD medications % of enrollees 18 years of age or younger on ADHD medications with evidence of a dose higher than the recommended maximum during the measurement period Numerator: Those in the denominator with evidence of a dose higher than the recommended maximum Denominator: The number of children 18 years of age or younger who were prescribed at least one stimulant medication for 30 days or more during the measurement year See Appendix D for ADHD dose guidelines While the most effective and tolerable dose of medication varies from individual to individual, studies suggest that doses higher than recommended are not generally associated with improved clinical response. High dosing also increases the risk for poor adherence and adverse side effects. Research suggests that children and youth are particularly vulnerable to adverse effects of psychotropic medications. In children, high doses of stimulants can cause insomnia and appetite suppression. Medicaid Claims & Encounter Data Pharmacy Files Eligibility Files B
QualityMeasures.docx